TOKYO -- Activist funds posting strong returns and expanding with institutional investors' backing are increasingly homing in on megacap stocks and companies verging on that status in the U.S., Japan and beyond, going after the likes of Disney, Pfizer and SoftBank Group.
At an investor conference in November, Pfizer CFO David Denton said in response to a question about activist investors that the U.S. pharmaceutical company is constantly examining its business model to see if any of its assets would be better served outside the company than inside.
.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
.png?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)